SG11202001264UA - Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction - Google Patents
Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunctionInfo
- Publication number
- SG11202001264UA SG11202001264UA SG11202001264UA SG11202001264UA SG11202001264UA SG 11202001264U A SG11202001264U A SG 11202001264UA SG 11202001264U A SG11202001264U A SG 11202001264UA SG 11202001264U A SG11202001264U A SG 11202001264UA SG 11202001264U A SG11202001264U A SG 11202001264UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating neurological
- neurological dysfunction
- indazole compounds
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001264UA true SG11202001264UA (en) | 2020-03-30 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001264UA SG11202001264UA (en) | 2017-08-16 | 2018-08-16 | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10508105B2 (ru) |
| EP (1) | EP3668865A1 (ru) |
| JP (1) | JP7253832B2 (ru) |
| KR (1) | KR20200054204A (ru) |
| CN (1) | CN111225913B (ru) |
| AU (1) | AU2018317403B2 (ru) |
| BR (1) | BR112020003292A2 (ru) |
| CA (1) | CA3072493A1 (ru) |
| CL (1) | CL2020000360A1 (ru) |
| CO (1) | CO2020002576A2 (ru) |
| EA (1) | EA202090467A1 (ru) |
| IL (1) | IL272575B2 (ru) |
| PE (1) | PE20200756A1 (ru) |
| SG (1) | SG11202001264UA (ru) |
| UA (1) | UA128084C2 (ru) |
| WO (1) | WO2019036534A1 (ru) |
| ZA (1) | ZA202001321B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089546A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CA3072493A1 (en) | 2017-08-16 | 2019-02-21 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| TW202116754A (zh) | 2019-07-11 | 2021-05-01 | 美商Ｅ 斯蓋普生物股份有限公司 | 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2024121367A1 (en) * | 2022-12-08 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Novel substituted pyrazine-carboxamide-imidazopyridine derivatives |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| EA017852B1 (ru) | 2006-12-20 | 2013-03-29 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные замещенных индазолов, активные в качестве ингибиторов киназ |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2010088406A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US20120184556A1 (en) | 2009-07-23 | 2012-07-19 | Conn P Jeffrey | Substituted enzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| EP2473055A4 (en) | 2009-09-04 | 2013-02-13 | Univ Vanderbilt | ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| WO2011050316A1 (en) | 2009-10-22 | 2011-04-28 | Vanderbilt University | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CA2780128A1 (en) | 2009-11-06 | 2011-05-12 | P. Jeffrey Conn | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP5883399B2 (ja) | 2010-02-11 | 2016-03-15 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 |
| KR20120120416A (ko) | 2010-02-11 | 2012-11-01 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 |
| MX2012013031A (es) | 2010-05-12 | 2012-12-17 | Univ Vanderbilt | Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica. |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016115282A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089546A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CA3072493A1 (en) | 2017-08-16 | 2019-02-21 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
-
2018
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 KR KR1020207007596A patent/KR20200054204A/ko active IP Right Grant
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en unknown
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US20220259190A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220259190A1 (en) | 2022-08-18 |
| IL272575B1 (en) | 2023-05-01 |
| JP7253832B2 (ja) | 2023-04-07 |
| US20190055225A1 (en) | 2019-02-21 |
| WO2019036534A1 (en) | 2019-02-21 |
| US20200291019A1 (en) | 2020-09-17 |
| BR112020003292A2 (pt) | 2020-08-18 |
| EP3668865A1 (en) | 2020-06-24 |
| AU2018317403B2 (en) | 2023-09-21 |
| CO2020002576A2 (es) | 2020-04-01 |
| CL2020000360A1 (es) | 2020-07-31 |
| ZA202001321B (en) | 2023-10-25 |
| KR20200054204A (ko) | 2020-05-19 |
| EA202090467A1 (ru) | 2020-06-18 |
| IL272575B2 (en) | 2023-09-01 |
| UA128084C2 (uk) | 2024-04-03 |
| IL272575A (en) | 2020-03-31 |
| US10508105B2 (en) | 2019-12-17 |
| AU2018317403A1 (en) | 2020-03-12 |
| US11427573B2 (en) | 2022-08-30 |
| JP2020531454A (ja) | 2020-11-05 |
| CN111225913B (zh) | 2024-05-31 |
| CN111225913A (zh) | 2020-06-02 |
| PE20200756A1 (es) | 2020-07-27 |
| CA3072493A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272575A (en) | Indazole compounds as allosteric enhancers of MGLUR4, compositions and methods for treating neurological dysfunction | |
| HK1252741A1 (zh) | 用於治療神經疾病的組合物和方法 | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| IL272844A (en) | Compounds, preparations and methods for the treatment or prevention of cancers resistant to HER-motor drugs | |
| IL288278A (en) | Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith | |
| EP2533642A4 (en) | BENZISOXAZOLES AND AZABENZISOXAZOLES AS ALLOSTERIC POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTOR SUBType 4 (MGLUR4), COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS | |
| GB2558326B (en) | Methods and compositions for inhibiting and treating neurological conditions | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| IL259861A (en) | Methods and preparations for the treatment of disorders related to seizures | |
| IL274837A (en) | Methods and preparations for the treatment of cancer | |
| SG10202109912XA (en) | Methods and compositions for treating cancers using antisense | |
| IL271256A (en) | Preparations and methods for the treatment of teopathy | |
| IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
| IL269637A (en) | Preparations and methods for the treatment of synovial diseases | |
| IL263697A (en) | Compounds, preparations and methods for the treatment and/or prevention of cancer | |
| IL272246A (en) | Preparations and methods for treating galactosemia | |
| PL3573620T3 (pl) | Kompozycje do leczenia nadciśnienia | |
| IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| IL273850A (en) | Preparations and methods for the treatment of leprosy | |
| IL269550A (en) | Preparations and methods for treating diseases related to alpha-synuclein | |
| PT3386527T (pt) | Composições para uso no tratamento ou melhoria da neuroinflamação, neurodegeneração, dor neuropática e enxaqueca | |
| HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 |